SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor against the SARS-CoV-2 protease 3CL(pro) that has been licensed for clinical use. To identify mutations that confer resistance to this protease inhibitor, we engineered a chimeric vesicular...

Descripción completa

Detalles Bibliográficos
Autores principales: Heilmann, Emmanuel, Costacurta, Francesco, Moghadasi, Seyed Arad, Ye, Chengjin, Pavan, Matteo, Bassani, Davide, Volland, Andre, Ascher, Claudia, Weiss, Alexander Kurt Hermann, Bante, David, Harris, Reuben S., Moro, Stefano, Rupp, Bernhard, Martinez-Sobrido, Luis, von Laer, Dorothee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765458/
https://www.ncbi.nlm.nih.gov/pubmed/36194133
http://dx.doi.org/10.1126/scitranslmed.abq7360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765458/
https://www.ncbi.nlm.nih.gov/pubmed/36194133
http://dx.doi.org/10.1126/scitranslmed.abq7360

Ejemplares similares